ArticlePloS one2009
Human erythrocytes selectively bind and enrich infectious HIV-1 virions.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 61 citations in OpenAlex.
- Porcine Erythrocyte-PRRSV Interactions: Implications for Targeted Nanodrug Delivery.Veterinary sciences · 2026Article
- Human erythrocytes' perplexing behaviour: erythrocytic microRNAs.Molecular and cellular biochemistry · 2025Review
- Vitamin C-Dependent Uptake of Non-Heme Iron by Enterocytes, Its Impact on Erythropoiesis and Redox Capacity of Human Erythrocytes.Antioxidants (Basel, Switzerland) · 2024Review
- Cell-nanocarrier drug delivery system: a promising strategy for cancer therapy.Drug delivery and translational research · 2024Review
- Article
- Prediction of in-hospital recurrence and false-negative results in patients with COVID-19 by red blood cell values on admission.Experimental and therapeutic medicine · 2021Article
- Human erythrocytes, nuclear factor kappaB (NFκB) and hydrogen sulfide (HCell cycle (Georgetown, Tex.) · 2021Article
- The CD147 Protein Complex Is Involved in Entry of Chikungunya Virus and Related Alphaviruses in Human Cells.Frontiers in microbiology · 2021Article
- Coronavirus disease 2019 (COVID-19), human erythrocytes and the PKC-alpha/-beta inhibitor chelerythrine -possible therapeutic implication.Cell cycle (Georgetown, Tex.) · 2020Review
- Do Blood Group Antigens and the Red Cell Membrane Influence Human Immunodeficiency Virus Infection?Cells · 2020Review
- CD71mBio · 2019Article
- Combining 25-Hydroxycholesterol with an HIV Fusion Inhibitor Peptide: Interaction with Biomembrane Model Systems and Human Blood Cells.ACS infectious diseases · 2019Article
- Red Blood Cells: Chasing Interactions.Frontiers in physiology · 2019Review
- Bone marrow stem cells to destroy circulating HIV: a hypothetical therapeutic strategy.Journal of biological research (Thessalonike, Greece) · 2018Article
- The Evolving Erythrocyte: Red Blood Cells as Modulators of Innate Immunity.Journal of immunology (Baltimore, Md. : 1950) · 2018Review
- Human complement receptor type 1 (CR1) protein levels and genetic variants in chronic Chagas Disease.Scientific reports · 2018Article
- Geographical distribution of complement receptor type 1 variants and their associated disease risk.PloS one · 2017Article
- Erythrocyte and blood antibacterial defense.European journal of microbiology & immunology · 2014Article
- Impact on red blood cell immunity patterns in postoperative phase following total hip arthroplasty.Central-European journal of immunology · 2014Article
- Platelet activation suppresses HIV-1 infection of T cells.Retrovirology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although CD4(+) cells represent the major target for HIV infection in blood, claims of complement-independent binding of HIV-1 to erythrocytes and the possible role of Duffy blood group antigen, have generated controversy. To examine the question of binding to erythrocytes, HIV-1 was incubated in vitro with erythrocytes from 30 healthy leukapheresis donors, and binding was determined by p24 analysis and adsorption of HIV-1 with reduction of infectivity for CD4(+) target cells. All of the cells, regardless of blood group type, bound HIV-1 p24. A typical preparation of erythrocytes bound <2.4% of the added p24, but erythrocytes selectively removed essentially all of the viral infectivity as determined by decreased infection of CD4(+) target cells; however, cell-associated HIV-1 was approximately 100-fold more efficient, via trans infection, than unadsorbed virus for infection of CD4(+) cells. All of the bound HIV-1 p24 was released by treatment of the cells with EDTA, and binding was optimized by adding Ca(2+) and Mg(2+) during the washing of erythrocytes containing bound HIV-1. Although the small number of contaminating leukocytes in the erythrocyte preparation also bound HIV-1 p24, there was no significant binding to CD4, and it thus appears that the binding occurred on leukocytes at non-CD4 sites. Furthermore, binding occurred to erythrocyte ghosts from which contaminating leukocytes had been previously removed. The results demonstrate that erythrocytes incubated in vitro with HIV-1 differentially adsorb all of the infectious HIV-1 virions (as opposed to non-infectious or degraded virions) in the absence of complement and independent of blood group, and binding is dependent on divalent cations. By analogy with HIV-1 bound to DC-SIGN on dendritic cells, erythrocyte-bound HIV-1 might comprise an important surface reservoir for trans infection of permissive cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.